Taiwan Liposome Company Ltd ADR (TLC)
Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the...
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks...
TLC Announces TLC599 Agreement with Endo
One of the largest deals seen in Taiwan’s biotech sector...
TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication...
Seattle Inno Under 25: Afeef Sheikh, The Literary Crusade founder
TLC Announces Details of Stock Swap Transactions
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
Taiwan Liposome is Now Oversold (TLC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
TLC Crosses Below Key Moving Average Level
In trading on Tuesday, shares of Taiwan Liposome Co Ltd (TLC) crossed below their 200 day moving average of $5.02, changing hands as low as $5.01 per share. Taiwan Liposome Co Ltd shares are currently trading down about 3.1% on the day..
TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years Running
Praised as benchmark for small and medium-sized enterprises